JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Mocetinostat (formerly MGCD-0103 or MG-0103), is a potent, benzamide-based and orally bioavailable Class I-selective inhibitor of human histone deacetylases (HDAC) with potentianl anticancer activities. Mocetinostat inhibits class I HDACs such as HDAC1/2/3 and class IV (e.g. HDAC11) with IC50s of 0.15 umol/L, 0.29 umol/L, 1.66 umol/L, and 0.59 umol/L respectively, exhibits little/no inhibition aganist class II HDACs (HDAC4-8). It is currently undergoing clinical trials for treating various types of cancers including follicular lymphoma, Hodgkin's lymphoma and acute myelogenous leukemia.
References: Mol Cancer Ther. 2008 Apr; 7(4):759-68; Circ Res. 2012 Mar 2; 110(5):739-48.
Related CAS #: 726169-73-9 (free base); 944537-89-7 (HBr)
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!